Table 3.
Subsequent therapya received in the Asian subpopulation of CheckMate 9LA
| Subsequent therapy, n (%) | Asian patients | Asian patients with a PFS event per BICRd | ||
|---|---|---|---|---|
| NIVO + IPI + chemob (n = 28) | Chemoc (n = 30) | NIVO + IPI + chemob (n = 22) | Chemoc (n = 29) | |
| Any subsequent therapy | 18 (64) | 25 (83) | 18 (82) | 25 (86) |
| Subsequent radiotherapy | 6 (21) | 11 (37) | 6 (27) | 11 (38) |
| Subsequent systemic therapy | 17 (61) | 23 (77) | 17 (77) | 23 (79) |
| Immunotherapy | 2 (7) | 20 (67) | 2 (9) | 20 (69) |
| Anti–PD-1 | 0 | 15 (50) | 0 | 15 (52) |
| Anti–PD-L1 | 1 (4) | 4 (13) | 1 (4) | 4 (14) |
| Other immunotherapy | 1 (4) | 2 (7) | 1 (4) | 2 (7) |
| VEGFR inhibitors | 6 (21) | 6 (20) | 6 (27) | 6 (21) |
| Other systemic therapy—experimental | 1 (4) | 1 (3) | 1 (4) | 1 (3) |
| Other systemic therapy—chemotherapy | 16 (57) | 11 (37) | 16 (73) | 11 (38) |
BICR blinded independent central review, Chemo chemotherapy, IPI ipilimumab, n number of patients, NIVO nivolumab, PD-1 programmed death-1, PD-L1 programmed death ligand-1, PFS progression-free survival, VEGFR vascular endothelial growth factor receptor
aDefined as therapy initiated on or after first dosing date (or randomization date if the patient was never treated); patients may have received more than 1 type of subsequent therapy
bNivolumab plus ipilimumab combined with chemotherapy (2 cycles)
cChemotherapy alone (4 cycles, with optional pemetrexed maintenance for nonsquamous histology)
dIncludes patients that had an event of progression or death as well as being censored for subsequent systemic therapy